BJU Int

1. NOURMOHAMMADI ABADCHI S, Salles DC, Flannery C, Sama V, et al
   Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.
   BJU Int. 2024;134:939-944.
   

   >> Share

   
   
2. MERSEBURGER AS, Agarwal N, Bjartell A, Uemura H, et al
   Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
   BJU Int. 2024;134:982-991.
   

   >> Share

   
   

   
   BMC Cancer

3. NGOWI BN, Mremi A, Mbwambo OJ, Seventh F, et al
   Trend in incidence and clinicopathological characteristics of prostate cancer in Northern Tanzania: analysis from a population based cancer registry data 2015-2021.
   BMC Cancer. 2024;24:1424.
   

   >> Share

   
   
4. MEHNERT E, Moller FS, Hofbauer C, Weidlich A, et al
   Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.
   BMC Cancer. 2024;24:1431.
   

   >> Share

   
   

   
   Clin Imaging

5. BLYTHE JA, Ng TSC
   Ethical principles for practice building in the era of targeted radioligand therapy.
   Clin Imaging. 2024;116:110334.
   

   >> Share

   
   

   
   Eur Urol

6. DAHM P, Wilt TJ
   Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
   Eur Urol. 2024 Nov 15:S0302-2838(24)02687-3. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
7. HUGOSSON J
   Population-based Screening for Prostate Cancer: Is it Time?
   Eur Urol. 2024 Nov 20:S0302-2838(24)02696-4. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   

   
   Int J Radiat Oncol Biol Phys

8. ARCANGELI S, Chissotti C, Ferrario F, Lucchini R, et al
   Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study.
   Int J Radiat Oncol Biol Phys. 2024;120:1394-1403.
   

   >> Share

   
   
9. SONG D, Dabkowski M, Costa P, Nurani R, et al
   Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy.
   Int J Radiat Oncol Biol Phys. 2024;120:1410-1420.
   

   >> Share

   
   
10. FUKUOKAYA W, Miki K, Aoki M, Takahashi H, et al
    Ten-year outcomes of a phase III, multicenter, randomized controlled trial (SHIP0804) with three-month neoadjuvant androgen deprivation prior to (125)I-seed transperineal prostate brachytherapy followed by nil versus nine-month adjuvant hormonal thera
    Int J Radiat Oncol Biol Phys. 2024 Nov 15:S0360-3016(24)03584.
    

    >> Share

    
    

    
    J Natl Cancer Inst

11. HAMMARLUND N, Holt SK, Etzioni R, Morehead D, et al
    The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.
    J Natl Cancer Inst. 2024 Nov 20:djae302. doi: 10.1093.
    

    >> Share

    
    
12. ZHAO Y, Gulati R, Yang Z, Newcomb L, et al
    Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
    J Natl Cancer Inst. 2024 Nov 20:djae296. doi: 10.1093.
    

    >> Share

    
    

    
    J Urol

13. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
    High 11-ketotestosterone linked to shorter time to castration resistance in recurrent non-metastatic prostate cancer.
    J Urol. 2024 Nov 15:101097JU0000000000004333. doi: 10.1097/JU.0000000000004333.
    

    >> Share

    
    

    
    JAMA

14. AJJAWI I, Loeb S, Cooperberg MR, Catalona WJ, et al
    Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020.
    JAMA. 2024 Nov 20:e2420580. doi: 10.1001/jama.2024.20580.
    

    >> Share

    
    

    
    Oncogene

15. RHEE JW, Adzavon YM, Sun Z
    Stromal androgen signaling governs essential niches in supporting prostate development and tumorigenesis.
    Oncogene. 2024;43:3419-3425.
    

    >> Share

    
    

    
    PLoS One

16. 
    Retraction: Human Chorionic Gonadotropin beta Induces Migration and Invasion via Activating ERK1/2 and MMP-2 in Human Prostate Cancer DU145 Cells.
    PLoS One. 2024;19:e0314356.
    

    >> Share

    
    
17. PAPADOPOULOS E, Wong AKO, Law SHC, Zhang LZJ, et al
    Correction: The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
    PLoS One. 2024;19:e0314372.
    

    >> Share

    
    
18. TANG Z, Li S, Zeng M, Zeng L, et al
    The association between systemic immune-inflammation index and prostate-specific antigen: Results from NHANES 2003-2010.
    PLoS One. 2024;19:e0313080.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

19. KOHRT SE, Novak EJ, Tapadar S, Wu B, et al
    Small-molecule disruption of androgen receptor-dependent chromatin clusters.
    Proc Natl Acad Sci U S A. 2024;121:e2406239121.
    

    >> Share

    
    

    
    Prostate

20. 
    RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
    Prostate. 2024 Nov 17. doi: 10.1002/pros.24822.
    

    >> Share

    
    
21. NAGASAKA H, Sato S, Suzuki A, Terao H, et al
    Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer.
    Prostate. 2024 Nov 20. doi: 10.1002/pros.24825.
    

    >> Share

    
    

    
    Semin Oncol

22. YAKOUT IA, Gallab MM, Mohamed DA, Hamdar H, et al
    Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: A systematic review and meta-analysis.
    Semin Oncol. 2024 Oct 29:S0093-7754(24)00053.
    

    >> Share

    
    

    
    Urology

23. TAY KJ
    Editorial Comment on "5-year Oncologic Outcomes Following Primary Partial Gland Cryo-Ablation (PPGCA) Prospective Cohort Study of Men with Intermediate-Risk Prostate Cancer".
    Urology. 2024 Nov 19:S0090-4295(24)01066-5. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share